ArticleFrontiers in psychiatry2025
Body mass index is associated with the antidepressant effects of intravenous ketamine in patients with depression.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- The Association Between BMI and Depression Symptoms Among College Students: A Study Based on Random Intercept Cross-Lagged Model.Behavioral sciences (Basel, Switzerland) · 2026Article
- Ketamine or Esketamine in Special Populations of Patients With Treatment-Resistant Depression.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: We aimed to explore the correlation between baseline body mass index (BMI) and the antidepressant properties of intravenous ketamine in patients with depression. Methods: We divided 135 patients diagnosed with either major depressive disorder (n=103) or bipolar depression (n=32) into lower and higher BMI groups based on their baseline BMI. Patients with a lower BMI (BMI<24 kg/m²; n=92) were included in the lower BMI group, and those with a higher BMI (BMI≥24 kg/m²; n=43) were assigned to the higher BMI group. Each participant received six ketamine infusions. Antidepressant remission was determined using a Montgomery-Åsberg Depression Rating Scale (MADRS; total score of ≤10) within 24 hours after the sixth ketamine infusion on day 13. Antidepressant response was characterized by a ≥50% alleviation in the symptoms of depression at the same time point. Changes in symptoms of depression over time were assessed using a linear mixed model. Results: The antidepressant response rate in the higher BMI group (67.4%, 95% confidence interval [CI]: 53.5%-81.4%) was higher than that in the lower BMI group (51.1%, 95% CI: 41.3%-60.9%). In addition, the remission rate was higher in the higher BMI group (39.5%, 95% CI: 25.6%-55.8%) than in the lower BMI group (31.5%, 95% CI: 21.7%-41.3%). However, these differences were not significant (all Conclusion: Our exploratory,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.